Cost-Based Estimated Price Algorithm for Insulins and Injectable and Glucagonlike Peptide 1 Agonists (GLP1As)

Authors of the study: Melissa J. Barber, PhD; Dzintars Gotham, MBBS; Helen Bygrave, MBBS; Christa Cepuch, MPH (Openverse / BY 4.0) / Openverse BY 4.0

Living With T1D/June 26, 2026/2 min read

How Do Modern Insulins Compare? What a Major Review Found About Fast-Acting Insulin Options

Researchers analyzed decades of studies comparing newer fast-acting insulins to older human insulin. Here's what the evidence shows for people using multiple daily injections.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

living with t1dmental healthtechnologysupport

Key takeaways

Fast-acting insulin analogues are designed to work more quickly than regular human insulin, but their real-world benefits remain unclear
This major review examined studies lasting at least 24 weeks to fairly compare how different insulins affect blood sugar control, low blood sugar episodes, and quality of life
Understanding which insulin option works best for you depends on your individual needs—not a one-size-fits-all answer

Why This Question Matters

If you use insulin injections multiple times a day, you've probably wondered whether the newer, faster-acting insulins are genuinely better than older options. It's a practical question: Do they control blood sugar more effectively? Do they cause fewer low blood sugar episodes? Do they improve daily life?

These aren't new insulins—they've been around for years—but the scientific evidence comparing them has been scattered across many different studies with different designs. A major new review from the Cochrane Collaboration, a trusted source for summarizing research, aimed to bring all that evidence together and see what it actually shows.

What the Researchers Did

Scientists searched medical databases from their start through May 2025 for all rigorous, randomized controlled trials comparing fast-acting and ultra-fast-acting insulin analogues to regular human insulin or to each other. They focused only on studies that lasted at least 24 weeks—long enough to see real effects—in adults with type 1 diabetes using multiple daily injections.

They looked at outcomes that matter most to people living with type 1: blood sugar control (HbA1c), how often people experience hypoglycemia (low blood sugar), diabetic ketoacidosis (a serious complication), quality of life, and how well people stick to their treatment plan.

What Comes Next

This review is being published in 2026, and it represents the most thorough comparison of fast-acting insulin options to date. Rather than relying on single studies or manufacturer claims, it pools evidence from many trials to see what patterns emerge.

The findings will help patients, parents, and doctors make more informed choices about which insulin type might work best for a particular person's needs and lifestyle. If your care team is discussing insulin options with you, this research can be part of that conversation—though your individual medical situation always comes first.

Evidence label

Source: The Cochrane database of systematic reviews. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.